CAS 1217510-38-7

Itraconazole-d5

CAS : 1217510-38-7

Formule : C₃₅H₃₃D₅Cl₂N₈O₄

Masse moléculaire : 710.67

Ref: 4Z-I-033

Itraconazole Impurity 5

CAS : 1217510-38-7, 84625-61-6

Formule : C₃₄H₃₅Cl₂N₈O₄·Cl

Couleur et forme : Yellow Solid

Masse moléculaire : 690.61 35.45

Ref: 4Z-I-0331

Itraconazole-d5 (major)

Produit contrôlé

CAS : 1217510-38-7

Applications An isotopically labelled, orally active antimycotic structurally related to Ketoconazole.A representative lot was 88% d5, 12% d4 with no d0. It is a COVID19-related research product.
References Espinel-Ingroff, A., et al.: Antimicrob. Agents Chemother., 26, 5 (1984), Heykants, J., et al.: Mycoses, 32, Suppl 1, 67 (1989), Sugar, A.M., et al.: Curr. Clin. Top. Infect. Dis., 13, 74 (1993),

Formule : C₃₅₂H₅H₃₃Cl₂N₈O₄

Couleur et forme : Neat

Masse moléculaire : 710.66

Ref: TR-I937502

Itraconazole-d5 (major)

CAS : 1217510-38-7

Itraconazole-d5 is a fluorescent derivative of itraconazole that is used for the detection of eosinophil cationic protein in the diagnosis of asthma. It binds to wild-type strains and inhibits fungal enzyme activities, such as concentration–time curves and minimal toxicity. The hydrogen bonding interactions between itraconazole-d5 and its target molecule are stronger than those between itraconazole and its target molecule. Itraconazole-d5 has been shown to inhibit the production of cationic proteins by inhibiting the activity of enzymes, such as polymerase chain reaction (PCR) and reverse transcriptase (RT), which are required for DNA synthesis.

Formule : C₃₅H₃₈Cl₂N₈O₄

Degré de pureté : Min. 95%

Masse moléculaire : 710.7 g/mol

Ref: 3D-SYB51038